NewAmsterdam Pharma N.V. (NAMSW)
8.99
-1.47 (-14.05%)
At close: Mar 31, 2025, 3:55 PM
NewAmsterdam Pharma Balance Sheet Statement
| Year | FY24 | FY23 | FY22 | FY21 | FY20 |
| Cash & Equivalents | 771.74M | 340.45M | 438.52M | 53.09M | 7.86M |
| Short-Term Investments | 62.45M | n/a | n/a | n/a | n/a |
| Long-Term Investments | n/a | n/a | n/a | 718.35K | 112.79M |
| Other Long-Term Assets | n/a | 35K | 146K | -353 | -112.79M |
| Receivables | n/a | 1.88M | 2.07M | 4.86M | n/a |
| Inventory | n/a | n/a | 21.5K | -735 | n/a |
| Other Current Assets | 29.22M | 4.46M | 8.18M | 7.47M | 1.67M |
| Total Current Assets | 863.41M | 346.79M | 448.13M | 58.87M | 9.22M |
| Property-Plant & Equipment | 673K | 101K | 144K | 190K | 12K |
| Goodwill & Intangibles | 534K | 170K | 83.16M | n/a | n/a |
| Total Long-Term Assets | 1.21M | 306K | 83.45M | 908K | 12K |
| Total Assets | 864.62M | 347.1M | 531.58M | 59.78M | 9.23M |
| Account Payables | 4.74M | 16.92M | 11.85M | 7.04M | 487.06K |
| Deferred Revenue | 6.01M | 8.94M | 13.01M | 3.61M | n/a |
| Short-Term Debt | 492K | 60K | 66K | 60.01K | 11.65M |
| Other Current Liabilities | 95.67M | 23.97M | 9.67M | 1.31M | 670.94K |
| Total Current Liabilities | 106.92M | 49.9M | 35.46M | 9.88M | 12.81M |
| Long-Term Debt | 202K | n/a | 60K | 125.68K | n/a |
| Other Long-Term Liabilities | n/a | 7.79M | 6.75M | -14.68K | n/a |
| Total Long-Term Liabilities | 202K | 8.81M | 11.6M | 111K | 9.95M |
| Total Liabilities | 107.12M | 58.7M | 47.06M | 9.99M | 12.81M |
| Total Debt | 448K | 60K | 118K | 164K | 11.65M |
| Common Stock | 13.44M | 10.17M | 599.19M | 83.88M | 2.5M |
| Retained Earnings | n/a | -316.97M | -119.36M | -34.68M | -6.08M |
| Comprehensive Income | 4.47M | 4.42M | 4.69M | 591K | n/a |
| Shareholders Equity | 757.5M | 288.39M | 484.52M | 49.79M | -3.58M |
| Total Investments | 62.45M | -31.08M | n/a | 718.35K | 112.79M |